Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Nipun B. Merchant

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3399-9776; OpenAlex author ID A5016606073; NIH RePORTER profile ID 6714805. Sources: ClinicalTrials.gov.

Their work

Papers
79 (first author 4, last author 16)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
2
Collaborators
281
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 4 papers · 2013: 5 papers · 2014: 8 papers · 2015: 2 papers, 1 grant · 2016: 3 papers · 2017: none · 2018: 3 papers · 2019: 7 papers · 2020: 5 papers · 2021: 8 papers · 2022: 7 papers, 1 grant · 2023: 7 papers · 2024: 6 papers · 2025: 10 papers · 2026: 3 papers

Papers 50 of 79

  1. IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancer. Co-author DOI 10.1172/jci.insight.202487↗
  2. Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18664-0↗
  3. ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18846-w↗
  4. Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.70130↗
  5. Pancreatic Cancer Patients Supportive Care Needs: A Qualitative Analysis. Co-author DOI 10.1002/pon.70135↗
  6. Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic c… Co-author DOI 10.1007/s00262-025-04096-y↗
  7. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  8. CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis. Co-author DOI 10.1016/j.jcmgh.2025.101606↗
  9. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  10. SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multic… Co-author DOI 10.1097/sla.0000000000006966↗
  11. Editor's Note: Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-25-1304↗
  12. Neighborhood Disadvantage is Associated with Worse Pathologic Response in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17024-2↗
  13. Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer Co-author DOI 10.64898/2025.12.04.691935↗
  14. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
  15. Tumor Cell-Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-23-1200↗
  16. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  17. Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer. Co-author DOI 10.21037/hbsn-23-668↗
  18. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Co-author DOI 10.3389/fonc.2024.1362244↗
  19. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  20. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
  21. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1046↗
  22. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-22-0329↗
  23. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  24. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  25. ASO Author Reflections: Racial Disparities in Chemoresponsivity in Localized Pancreatic Cancer: Nature or Nurture? Co-author DOI 10.1245/s10434-022-12843-z↗
  26. Texture Analysis Identifies Distinct Radiomic Signals Associated with Survival in Hispanic Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13013-x↗
  27. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  28. Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. Co-author DOI 10.1016/j.hpb.2022.05.003↗
  29. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Last author DOI 10.1038/s41388-022-02368-w↗
  30. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overco… Last author DOI 10.1053/j.gastro.2022.07.076↗
  31. Obesity enriches for tumor protective microbial metabolites and treatment refractory cells to confer therapy resistance in PDAC. Co-author DOI 10.1080/19490976.2022.2096328↗
  32. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-instit… Co-author DOI 10.1245/s10434-022-11804-w↗
  33. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy resp… Co-author DOI 10.7554/elife.78921↗
  34. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. Last author DOI 10.1001/jamasurg.2020.5676↗
  35. An Immunocompetent Model of Pancreatic Cancer Resection and Recurrence. Co-author DOI 10.1007/s11605-020-04681-9↗
  36. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  37. A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. Co-author DOI 10.1097/sla.0000000000004471↗
  38. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-19-1043↗
  39. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-21-0083↗
  40. Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last? First author DOI 10.1245/s10434-020-09400-x↗
  41. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  42. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. Co-author DOI 10.1002/cam4.3042↗
  43. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer? Last author DOI 10.1016/j.yasu.2020.05.001↗
  44. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. Co-author DOI 10.1093/carcin/bgz116↗
  45. Commentary on "Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer". Co-author DOI 10.1097/sla.0000000000004191↗
  46. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-19-0741↗
  47. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor … Co-author DOI 10.1002/cam4.2180↗
  48. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2019.06.016↗
  49. Does Neoadjuvant Chemotherapy Change the Role of Regional Lymphadenectomy in Pancreatic Cancer Survival? Last author DOI 10.1097/mpa.0000000000001339↗
  50. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Last author DOI 10.1097/sla.0000000000003468↗

Trials 1

  1. PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca Principal investigator NCT00467116↗

Grants 2

  1. Reprogramming the Tumor Microenvironment in Pancreas Cancer to Enhance Immunotherapy R01CA161976↗
  2. Translational Research Grant: Nipun Merchant (MEK and CDK4 inhibition of KRAS effectors) AWARD pancan:2015-nipun-merchant-md-translational-research-grant-nipun-merch

Closest collaborators

The 25 strongest of 281 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jashodeep Datta · 22 shared papers, 2021–2026 · strength 4.06
  2. Nagaraj S. Nagathihalli · 18 shared papers, 2015–2025 · strength 2.35
  3. Peter J. Hosein · 11 shared papers, 2019–2026 · strength 2.10
  4. Caitlin A. Hester · 8 shared papers, 2023–2026 · strength 1.87
  5. Siddharth Mehra · 12 shared papers, 2020–2025 · strength 1.79
  6. Austin R. Dosch · 13 shared papers, 2018–2025 · strength 1.68
  7. Erin M. Dickey · 7 shared papers, 2024–2026 · strength 1.61
  8. Haleh Amirian · 8 shared papers, 2023–2026 · strength 1.55
  9. Shishir Kumar Maithel · 11 shared papers, 2014–2025 · strength 1.53
  10. Iago De Castro Silva · 10 shared papers, 2021–2025 · strength 1.52
  11. Mary P Martos · 6 shared papers, 2024–2026 · strength 1.42
  12. Jashodeep Datta · 7 shared papers, 2021–2025 · strength 1.32
  13. Daniel Erik Abbott · 9 shared papers, 2014–2025 · strength 1.13
  14. David A. Kooby · 10 shared papers, 2012–2025 · strength 1.10
  15. Ifeanyichukwu Chinedu Ogobuiro · 6 shared papers, 2023–2025 · strength 1.06
  16. Supriya Srinivasan · 8 shared papers, 2018–2025 · strength 1.03
  17. Samara P. Singh · 7 shared papers, 2021–2025 · strength 1.02
  18. Syed Ameen Ahmad · 9 shared papers, 2012–2025 · strength 0.99
  19. Jason A. Castellanos · 9 shared papers, 2014–2025 · strength 0.91
  20. Michael Nathan VanSaun · 7 shared papers, 2018–2025 · strength 0.90
  21. Alexander A. Parikh · 9 shared papers, 2012–2025 · strength 0.89
  22. Gregory C. Wilson · 6 shared papers, 2014–2024 · strength 0.77
  23. Anna Bianchi · 4 shared papers, 2023–2026 · strength 0.76
  24. Chanjuan Shi · 8 shared papers, 2013–2025 · strength 0.68
  25. Chet W. Hammill · 4 shared papers, 2022–2025 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.